
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD19 CRISPR/Cas9 KO Plasmid (h2) | sc-400719-KO-2 | 20 µg | $397.00 | |||
CD19 HDR Plasmid (h2) | sc-400719-HDR-2 | 20 µg | $445.00 |
CD19 encodes a B cell–restricted transmembrane glycoprotein that functions as a coreceptor amplifying signaling downstream of the B cell antigen receptor. Through association with CD21/CD81 and recruitment of kinases and adaptors, CD19 enhances PI3K–AKT and MAPK pathway activation, shaping calcium flux, proliferation, and survival during B cell development and activation. Altered CD19 expression or signaling is linked to dysregulated humoral immunity and has been studied in the context of immunodeficiency, autoimmunity, and B cell malignancy biology. As a lineage-defining surface marker, CD19 is also widely used to interrogate B cell differentiation states and signaling network rewiring.
CD19 CRISPR/Cas9 KO Plasmid (h2) is a pool of plasmids designed for targeted disruption of the CD19 gene in human cell lines. Each plasmid in the pool co-expresses a unique sgRNA, targeting a distinct site within the CD19 locus, alongside the Streptococcus pyogenes Cas9 nuclease, and encodes GFP to enable fluorescent identification and enrichment of successfully transfected cells. This multi-guide strategy increases the likelihood of inducing frameshifts or deletions that produce a functional knockout, offering a more robust alternative to single-guide approaches. DSBs induced at multiple sites are resolved through non-homologous end joining (NHEJ) or, when used with the included HDR donor template, homology-directed repair (HDR) at a defined target site within the locus.
When used in conjunction with the RFP-expressing HDR donor, GFP and RFP fluorescence can be used together to distinguish transfected from edited cell populations, streamlining flow cytometry-based sorting and clone selection workflows.
For applications requiring confirmed, selectable knockout clones, CD19 HDR Plasmid (h2) includes an HDR donor construct containing a puromycin resistance cassette (PuroR) and a red fluorescent protein (RFP) reporter, flanked by homology arms specific to a defined CD19 target site.
When co-transfected with CD19 CRISPR/Cas9 KO Plasmid (h2):
The HDR donor construct features loxP sites flanking the PuroR-RFP selection cassette to allow clean marker removal following clone confirmation. Transient expression of Cre recombinase via the included Cre Vector: sc-418923 excises the cassette, leaving a minimal residual loxP site within the CD19 locus and eliminating potential confounding effects on downstream assays.
This two-step approach:
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.